In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS)

Journal of Controlled Release

Volumn 160, Issue 1, 2012, Pages 25-32

  Thomas, N ^a   Holm, R ^b   Mullertz A ^c   Rades, T ^a,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amorphous; Bioavailability; Precipitation; SNEDDS; Supersaturation

Indexed keywords

BIOAVAILABILITY; COSOLVENTS; DRIVING FORCES; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; ENHANCED ABSORPTION; EQUILIBRIUM SOLUBILITIES; HALOFANTRINE; IN-VITRO; IN-VIVO; LONG CHAINS; POORLY WATER-SOLUBLE DRUGS; PREDICTIVITY; SNEDDS; SOLUBILISATION; SOYBEAN OIL;

AMORPHOUS MATERIALS; BIOCHEMISTRY; DISSOLUTION; DRUG DELIVERY; ETHANOL; LIPIDS; PELLETIZING; PRECIPITATION (CHEMICAL); SOLUBILITY; SUPERSATURATION; SURFACE ACTIVE AGENTS;

ENZYMES;

HALOFANTRINE; SOYBEAN OIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; SUPERSATURATED SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; GLYCERIDES; LIPOLYSIS; MALE; PARTICLE SIZE; PHENANTHRENES; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION;

EID: 84861529172     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.027     Document Type: Article

References (39)

1. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
2. S. Stegemann, F. Leveiller, D. Franchi, H. de Jong, and H. Linden When poor solubility becomes an issue: from early stage to proof of concept Eur. J. Pharm. Sci. 31 2007 249 261
3. S. Chakraborty, D. Shukla, B. Mishra, and S. Singh Lipid - an emerging platform for oral delivery of drugs with poor bioavailability Eur. J. Pharm. Biopharm. 73 2009 1 70
4. P.P. Constantinides Lipid microemulsions for Improving drug dissolution and oral absorption: physical and biopharmaceutical aspects Pharm. Res. 12 1995 1561 1572
5. D.H. Hauss Oral lipid-based formulations Adv. Drug Deliv. Rev. 59 2007 667 676
6. W.N. Humberstone Charman, lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug Deliv. Rev. 25 1997 103 128
7. C.J.H. Porter, C.W. Pouton, J.F. Cuine, and W.N. Charman Enhancing intenstinal drug solubilisation using lipid-based delivery systems Adv. Drug Deliv. Rev. 60 2008 673 691
8. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
9. D.G. Fatouros, B. Bergenstahl, and A. Müllertz Morphological observations on a lipid-based drug delivery system during in vitro digestion Eur. J. Pharm. Sci. 31 2007 85 94
10. D.G. Fatouros, I. Walrand, B. Bergenstahl, and A. Müllertz Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products Pharm. Res. 26 2008 361 374
11. T.D. Thi, M. Van Speybroeck, V. Barillaro, J. Martens, P. Annaert, P. Augustijns, J. Van Humbeeck, J. Vermant, and G. Van den Mooter Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS Eur. J. Pharm. Sci. 38 2009 479 488
12. J.F. Cuiné, C.L. Claire, L. McEvoy, W.N. Charman, C.W. Pouton, G.A. Edwards, H. Benameur, and C.J.H. Porter Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 97 2008 995 1012
13. J. Christensen, K. Schultz, B. Mollgard, H.G. Kristensen, and A. Müllertz Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols Eur. J. Pharm. Sci. 23 2004 287 296
14. A.M. Kaukonen, B.J. Boyd, C.J.H. Porter, and W.N. Charman Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations Pharm. Res. 21 2004 245 253
15. P. Gao, A. Akrami, F. Alvarez, J. Hu, L. Li, C. Ma, and S. Surapaneni Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption J. Pharm. Sci. 98 2009 516 528
16. P. Gao, B.D. Rush, W.P. Pfund, T. Huang, J.M. Bauer, W. Morozowich, M.-S. Kuo, and M.J. Hageman Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 92 2003 2386 2398
17. P.J. Sassene, M.M. Knopp, J.Z. Hesselkilde, V. Koradia, A. Larsen, T. Rades, and A. Müllertz Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate J. Pharm. Sci. 99 2010 4982 4991
18. J.F. Cuiné, W.N. Charman, C.W. Pouton, G.A. Edwards, and C.J.H. Porter Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs Pharm. Res. 24 2004 748 757
19. K. Moser, K. Kriwet, A. Naik, Y.N. Kalia, and R.H. Guy Passive skin penetration enhancement and its quantification in vitro Eur. J. Pharm. Biopharm. 52 2001 103 112
20. R.H. Müller, M. Radtke, and S.A. Wissing Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations Adv. Drug Deliv. Rev. 54 2002 S131 S155 (Supplement)
21. M.A. Pellett, S. Castellano, J. Hadgraft, and A.F. Davis The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro J. Control. Release 46 1997 205 214
22. C.J.H. Porter, S.A. Charman, and W.N. Charman Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion J. Pharm. Sci. 85 1996 351 356
23. G.A. Kossena, B.J. Boyd, C.J.H. Porter, and W.N. Charman Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs J. Pharm. Sci. 92 2003 634 648
24. A.J. Humberstone, G.J. Currie, C.J.H. Porter, M.J. Scanlon, and W.N. Charman A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions J. Pharm. Biomed. Anal. 13 1995 265 272
25. N. Thomas, A. Müllertz, A. Graf, and T. Rades Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems (SNEDDS) J. Pharm. Sci. 101 2012 1721 1731 10.1002/jps.23054
26. N.H. Zangenberg, A. Müllertz, H.G. Kristensen, and L. Hovgaard A dynamic in vitro lipolysis model: I. Controlling the rate of lipolysis by continuous addition of calcium Eur. J. Pharm. Sci. 14 2001 115 122
27. N.H. Zangenberg, A. Müllertz, H.G. Kristensen, and L. Hovgaard A dynamic in vitro lipolysis model: II: evaluation of the model Eur. J. Pharm. Sci. 14 2001 237 244
28. M.L. Lind, J. Jacobsen, R. Holm, and A. Müllertz Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80 Eur. J. Pharm. Sci. 35 2008 211 218
29. R. Holm, E.B. Jorgensen, M. Harborg, R. Larsen, P. Holm, A. Müllertz, and J. Jacobsen A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs Eur. J. Pharm. Sci. 42 2011 416 422
30. R. Holm, C. Porter, A. Müllertz, H. Kristensen, and W. Charman Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats Pharm. Res. 19 2002 1354 1361
31. C.J.H. Porter, and A.M. Kaukonen Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine J. Pharm. Sci. 93 2004 1110 1121
32. R. Holm, A. Müllertz, G.P. Pedersen, and H.G. Kristensen Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids Pharm. Res. 18 2001 1299 1304
33. S.-M. Khoo, D.M. Shackleford, C.J.H. Porter, and G.A. Edwards Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs Pharm. Res. 20 2003 1460 1465
34. G. Kossena, W. Charman, C. Wilson, B. O'Mahony, B. Lindsay, J. Hempenstall, C. Davison, P. Crowley, and C. Porter Low dose lipid formulations: effects on gastric emptying and biliary secretion Pharm. Res. 24 2007 2084 2096
35. A. Dahan, and H. Amnon Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J. Control. Release 129 2008 1 10
36. A.T. Larsen, P. Sassene, and A. Müllertz In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems Int. J. Pharm. 417 2011 245 255
37. A.J. Humberstone, C.J.H. Porter, and W.N. Charman A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine J. Pharm. Sci. 85 1996 525 529
38. A. Dahan, and A. Hoffmann Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats Pharm. Res. 23 2006 2165 2174
39. A. Larsen, R. Holm, M. Pedersen, and A. Müllertz Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis Pharm. Res. 25 2008 2769 2777